Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?

Juan WANG1,*, Da-Peng ZHANG1,*, Hong–Bin LIU2, Jiu–Chang ZHONG1, Xin–Chun YANG1

1Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China
2Department of Cardiology, People’s Liberation Army General Hospital, Beijing, China

Abstract

Hypertension has been found to be an increased risk of stroke in atrial fibrillation (AF). Both the European and U.S. guidelines advocate the use of the CHA2DS2-VASc (congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category) scheme for risk stratification. Although vitamin K antagonists is more effective than acetylsalicylic acid at preventing ischaemic stroke, its benefit is off by an increased haemorrhage risk. The risk of ischemic stroke in patients with AF and a CHA2DS2-VASc score of 1 are considered to be low risk and may be not expected to benefit from anticoagulation therapy. Hypertension carries an increased risk of ischemic stroke, however, it is also a clear risk factor for hemorrhage in AF. Therefore, the optimal antithrombotic management is highlighted in patients with AF with only one risk factor especially hypertension.

Keywords: Atrial fibrillation; Hypertension; Stroke

1 Introduction

Hypertension is the most common comorbid condition in patients with atrial fibrillation (AF). In particular, it was found in 49%–90% of individuals in AF trials.[1–4] Stroke prevention is a major goal in the treatment of patients with AF. Hypertension has been found to be an independent risk factor for stroke and patients with both AF and hypertension have an increased risk of stroke. Both the European and U.S. guidelines[5,6] advocate the use of the CHA2DS2-VASc (congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category) scheme for risk stratification. However, for low risk patients with a score of 1 on the CHA2DS2-VASc the guidelines are inconsistent. The European Society of Cardiology (ESC)[5] recommends treatment with either adjusted-dose vitamin K antagonists (VKAs) (e.g., warfarin) or, preferably, one of the non–vitamin K antagonist oral anticoagulants (NOACs) (i.e., dabigatran, rivaroxaban, apixaban). While the 2014 American Heart Association/American College of Cardiology (AHA/ACC) guideline[6] states that aspirin may be considered for AF patients with a CHA2DS2-VASc score of 1 as a potential alternative to oral anticoagulants (OACs) or no therapy. The recent Canadian guidelines[7] dichotomized individuals into those with versus without one risk factor for stroke, based on the CHA2DS2-VASc score. Although some of the CHA2DS2-VASc risk factors (e.g., age) are easy to validate, others such as hypertension are more complex. Uncontrolled hypertension leads to more strokes, whether in AF or non-AF patients. However, when anticoagulants are used, uncontrolled blood pressure increases the risk of serious bleeding. In addition, racial/ethnic also affect the optimal anticoagulation therapy. Incidence in intracranial hemorrhage (ICH) during warfarin treatment was approximately four times greater in the Asian than in the Caucasian. Asians were at successively greater ICH risk than whites.[8] Thus, it is of value to examine the strength of the data on hypertension alone as a risk factor for thromboembolism in AF.

2 Hypertension and thrombosis

Previous studies[9–11] have found that patients with hypertension demonstrate abnormalities of vessel wall (endothelial dysfunction or damage), blood constituents (abnormal levels of haemostatic factors, platelet activation and
fibrinolysis) and blood flow (rheology and flow reserve), suggesting that hypertension does indeed confer a prothrombotic or hypercoagulable state. In addition to the increased risk of thrombogenesis, hypertension also increases the risk of atherosclerosis, since both thrombogenesis and atherogenesis are intimately related. Thus, the pathophysiological changes in hypertension contribute to an intravascular microenvironment which promotes platelet adhesion, aggregation and thrombus formation, which is probably responsible for the excess risk of myocardial infarction, strokes and peripheral vascular disease. The rationale for the use of antithrombotic therapy on pathophysiological grounds alone would therefore seem highly plausible.

3 Stroke assessment in hypertensive patients with AF

Hypertension is frequently seen in patients with AF as those included in major clinical trials. Furthermore, hypertension has been frequently documented in patients (49%-90%) as those included in major AF clinical trials.[3,4,12,13] Compared with the general population, patients with AF have a 3- to 6-fold increase in stroke risk.[14] Hypertension worsens the stroke rate by an additional 2- to 3-fold in patients with AF.[15-17] Untreated or suboptimally treated hypertension leads to the development of left ventricular hypertrophy, which is one of the most important expressions of subclinical organ damage, and is an independent risk factor for cardiovascular events, including the development of AF. In the presence of left ventricular hypertrophy, left ventricular compliance is reduced, left ventricular stiffness and filling pressure increase, coronary flow reserve is decreased, wall stress is increased and there is activation of the sympathetic nervous system and of the renin–angiotensin–aldosterone system. In the atria, proliferation and differentiation of fibroblasts into myofibroblasts lead to the left atrial mechanical remodeling. It has been demonstrated that hypertension is associated with reduced left atrial appendage flow velocity, spontaneous echo contrast, and thrombus formation in patients with nonvalvular AF, thus resulting in cardioembolic stroke.[18,19] Nonetheless, hypertension can also increase the risk of non-cardioembolic stroke due to hypertensive damage to brain vessels leading to lacunar infarcts in patients with AF.[20,21] However, hypertension is not always detected as an independent predictor of thromboembolism or hemorrhagic complications. In previous reports in patients with nonvalvular AF who were not receiving anticoagulation therapy, hypertension was an independent risk factor for ischemic stroke.[22] whereas it was not in patients treated with warfarin.[23, 24] Since these analyses were performed post hoc on data from prospective clinical studies, patient characteristics varied among studies. More recently, systolic blood pressure (SBP) of ≥ 136 mmHg at the time closest to the event rather than the history of hypertension was an independent risk for thromboembolism and major hemorrhage.[25] The presence of AF in hypertensive patients should therefore prompt physicians to control the blood pressure. Given that uncontrolled elevation in SBP is a risk factor for intracranial hemorrhage and patients taking anticoagulants are at high risk for bleeding, it is not only relevant to determine the association between a history of hypertension requiring therapy, but also to determine whether patients with AF and hypertension benefit from anticoagulation treatment in the same way as those without.

4 Anticoagulation treatment in hypertension patients

Since hypertension is part of CHA2DS2-VASc risk score for stroke, and according to the guidelines, most of them should receive unless contra-indications exist, OACs to prevent stroke and other embolic events.[10] The risk of stroke in patients with AF can be reduced with anticoagulation, and VKAs have historically been the most commonly used therapy. Recently NOACs, including dabigatran, apixaban, rivaroxaban, and edoxaban, were approved for stroke prevention in nonvalvular AF.[15, 26, 27] All four NOACs share additional clinical advantages over warfarin due to better known and reproducible pharmacological profiles, fewer drugs to drugs interactions, absence of dietary effects, and substantially reduced risk of intracranial bleeding compared with warfarin. Indeed, in daily clinical practice a large proportion of patients with hypertension are older than 65, or are women therefore having a risk score of 2 or greater. Anticoagulation treatment should be given not only to patients with persistent or permanent AF, but also to those with paroxysmal AF, who should be regarded as having the same risk.

5 Antithrombotic therapy in AF with hypertension as the only risk factor

All guidelines[6, 28-31] recommend that patients with a CHA2DS2-VASc score of 2 or higher should be treated with OACs because the risk of ischaemic stroke outweighs the increased risk of bleeding induced by anticoagulation therapy. However, guidelines are less confirmed in their recommendations concerning patients with a CHA2DS2-VASc score of 1, reflecting uncertainty about the benefits of OACs.
Recent guidelines’ update strongly recommends focusing on the identification of “truly low-risk” patients with AF, instead of “high-risk” patients. Indeed, patients with AF who have stroke risk factor (s) ≥ 2 are recommended to receive effective stroke prevention therapy, which is OACs with either well-controlled VKA therapy (international normalized ratio (INR) 2–3, with a high percentage of time in the therapeutic range (TTR), for example, at least 70%) or one of the NOACs. The important unresolved issue is whether the CHA2DS2-VASc score improves risk discrimination in patients in whom it is unclear if treatment with anticoagulants is beneficial (i.e. those with a CHA2DS2-VASc score of 1). Hypertension, a common disease and the most frequent comorbidity in patients with AF, should be assessed for the risk of stroke or systemic embolism. However, most clinical trials of OACs did not usually have hypertension as the only entry criteria. In addition, for low risk patients with a score of 1 on the CHA2DS2-VASc, the thromboprophylaxis is inconsistent in guidelines. For low risk patients with a score of 1 on the CHA2DS2-VASc, the ESC recommends treatment with either an adjusted-dose VKAs (e.g., warfarin) or, preferably, one of the NOACs (i.e., dabigatran, rivaroxaban, apixaban). The 2014 National Institute for Health and Care Excellence (NICE) guidelines recommend a similar approach, and aspirin is not recommended. However, the 2014 ACC/AHA guidelines recommend OACs for patients with a CHA2DS2-VASc score ≥ 2 and no therapy for those with a CHA2DS2-VASc score of 0; for patients with a CHA2DS2-VASc score of 1, no therapy, aspirin, or OACs is recommended.

There are limit data on some patients with AF and a CHA2DS2-VASc score of 1 (which would include hypertension alone) who have very low stroke rates (Table 1). Coppens, et al. have first showed that patients with AF and a CHA2DS2-VASc score ≤ 1 (which would include hypertension alone) have very low stroke rates (0.9% or less per year) and they demonstrated these patients may not benefit from treatment with VKA therapy. Similarly, Friberg, et al. found that AF patients with CHA2DS2-VASc score of 1 had an annual stroke risk between 0.5% and 0.9%, even the endpoint was enriched with diagnoses of TIA, pulmonary embolism, arterial embolism, and stroke not specified as ischemic or hemorrhagic, the annual event rate for men was 1.3%, well below the 1.7% and 0.9% limits. Therefore anticoagulation treatment benefit is unlikely with warfarin or even with the newer drugs (dabigatran, rivaroxaban, or apixaban). Subsequently, the cost effectiveness of treatment will be low, or even negative, if treatment causes more harm than good. Lip, et al. conducted a retrospective study of 39,400 Danish patients discharged with incident nonvalvular AF and 0 or 1 CHA2DS2-VASc score reported that about 50% of patients with one risk factor had age as the only risk factor (≥ 65 years), and 90% had either age or hypertension as the main risk factors. Stroke event rates for untreated low-risk patients [CHA2DS2-VASc=0 (man), 1 (woman)] were 0.49% at one year and 0.47% at full follow-up (intention-to-treat; 5.9 years). However, with one additional stroke risk factor, stroke event rates at one year were 1.55% per year on intention-to-treat and increased by 3.01-fold without treatment. Otherwise, both aspirin and warfarin have reduced death significantly but increase bleeding at full follow up and the reduction in stroke is neutral in

| Study Type       | Coppens, et al.2013 | Huang, et al.2014 | Friberg, et al.2015 | Lip, et al.2015 | Suzuki, et al.2015 |
|------------------|---------------------|-------------------|---------------------|----------------|------------------|
| Sample Size      | 4670                | 548               | 140,420             | 39400          | 3588             |
| Hypertension     | 79%                 | 12%               | 43.8%               | 17.3%          | 50.4%            |
| Heart failure    | 6%                  | 4.5%              | 31.9%               | 1.8%           | 15%              |
| Diabetes mellitus| 3%                  | 2.5%              | 16.4%               | 25.6%          | 15.3%            |
| CHA2DS2-VASc = 0 | 35%                 | 7%                | 51.6%               | 17.2           |                  |
| CHA2DS2-VASc = 1 | 26%                 | 65%               | 8.80%               | 48.4%          | 20%              |
| Stroke rate for  | 0.9%                | 6.6%              | 0.5%–0.9%           | 0.49%          | 0.5%             |
| CHA2DS2-VASc = 1 |                     |                   |                     |                |                  |
| Women            | 34%                 | 19.2%             | 50.1%               | 37.8%          | 33.9%            |
| Men              | 48%                 | 0                 | 13.6%               | 41.8%          |                  |
| Aspirin          |                     |                   |                     |                |                  |
| Warfarin         | 0                   | 40%               | 26.6%               | 0              |                  |

CHA2DS2-VASc: congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke/transient ischemic attack (TIA), vascular disease, age 65–74 years, sex category.
patients with one additional stroke factor. In addition, Huang, et al.[37] in a cohort of 9727 Chinese AF patients, of which, 548 patients were entered into analysis, reported an annual incidence of stroke of 2.4 and 6.6% for patients with CHA2DS2-VASc score of 0 and 1, respectively, showing that patients with hypertension were at the highest risk of stroke [hazard ratio (HR): 9.8, 95% confidence intervals (CI): 2.7–35.6], followed by patients aged 65–74 (HR: 3.9, 95% CI: 2.3–6.6) and female sex (HR: 2.3, 95% CI: 1.1–4.8). The study showed that hypertension conferred the highest risk for stroke among other risk factors comprising the score.

A more aggressive thromboprophylaxis strategy may be justified among AF patients with CHA2DS2-VASc score of 1 due to hypertension. The presence of hypertensive in AF patients should therefore prompt physicians to control the blood pressure and consider anticoagulation therapy, particularly if there are other risk factors present, e.g. older age (> 75 years), heart failure or left ventricular dysfunction. However, hypertension is a clear risk factor for hemorrhagic stroke in the general population.[38] An increase in blood pressure levels during antithrombotic treatment was positively associated with the development of ICH, suggesting that adequate blood pressure control was important for avoiding ICH. [39] Furthermore, uncontrolled hypertension is an important risk factor for bleeding in anticoagulated subjects.[40] Previous analysis of pooled data from five randomized controlled trials demonstrated that the effect of aspirin was seen mainly among patients with a history of hypertension. In these patients the frequency of strokes was decreased by 59% (95% CI, 28% to 77%; P = 0.002), while among patients with no history of hypertension it was increased by 10% (95% CI, 40% to 100%; P = 0.76). The difference in the effectiveness of aspirin in patients with and without a history of hypertension was statistically significant (P = 0.02).[41] At present, no direct comparisons have been made between clopidogrel and aspirin and the new oral anticoagulants that have lower bleeding risks than warfarin in nonvalvular atrial fibrillation. [42] A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833.

Although the stroke risk of AF patients with CHA2DS2-VASc score of 1 was low, antithrombotic drugs options in these patients were inconsistent. Hypertension and AF commonly coexist and their combination carries an increased risk of stroke or systemic embolism. Hypertension in the presence of AF should be assessed for the risk of stroke or systemic embolism as a risk factor alone. In this review, we highlight the problems with using one factor such as hypertension as the only criterion for institution of antithrombotic therapy for patients with AF. Accurate antithrombotic therapy management may reduce the risk of ischemic stroke in these apparently low-risk patients with hypertension as the risk factor alone.

6 Conclusions

Although the stroke risk of AF patients with CHA2DS2-VASc score of 1 was low, antithrombotic drugs options for AF. We recognize that treatment adherence/discontinuation is an important consideration for patient management, but a thorough analysis is beyond the scope of this paper. Further studies are warranted to illustrate the question of whether patients with AF and CHA2DS2-VASc of 1 in particular when that risk factor is hypertension would be best managed with “nothing, aspirin, or warfarin”.

References

1. Hohnloser SH, Kuck KH, Lilienthal J, et al. Rhythm or rate control in atrial fibrillation—pharmacological intervention in atrial fibrillation (piaf): a randomised trial. Lancet 2000; 356: 1789–1794.
2. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833.
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
4. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.
5. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: an update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.
6. January CT, Wann LS, Alpert JS, et al. 2014 aha/acc/hr guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol 2014; 64: e1–e76.
7. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30:
1114–1130.
8 Shen AY, Chen W, Yao JF, et al. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. *CNS Drugs* 2008; 22: 815–825.
9 Vanhoutte PM. Endothelial dysfunction in hypertension. *J Hypertens Suppl* 1996; 14: S83–S93.
10 Lip GY, Blann AD, Jones AF, et al. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. *Am J Cardiol* 1997; 80: 1566–1571.
11 Li J, Zhao SP, Li XP, et al. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. *Int J Cardiol* 1997; 61: 165–169.
12 Le Heuzey JY, Breithardt G, Camm J, et al. The recordaf study: design, gw. Get(window, "data"), and profile of patients according to chosen treatment strategy for atrial fibrillation. *Am J Cardiol* 2010; 105: 687–693.
13 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; 361: 1139–1151.
14 Wolf PA, Abbott RD, Kannel WB, et al. Atrial fibrillation: a major contributor to stroke in the elderly. The famingham study. *Arch Intern Med* 1987; 147: 1561–1564.
15 Tohgi H, Tajima T, Konno T, et al. The risk of cerebral infarction in non-valvular atrial fibrillation: effects of age, hypertension and antihypertensive treatment. *Eur Neurol* 1991; 31: 126–130.
16 Predictors of thromboembolism in atrial fibrillation: li. Echocardiographic features of patients at risk. The stroke prevention in atrial fibrillation investigators. *Ann Intern Med* 1992; 116: 6–12.
17 Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. *JAMA* 2001; 285: 2864–2870.
18 Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation iii investigators. *J Am Coll Cardiol* 1998; 31: 1622–1626.
19 Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage [the stroke prevention in atrial fibrillation (spaf-iii) study]. *J Am Soc Echocardiogr* 1999; 12: 1080–1087.
20 Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Stroke prevention in atrial fibrillation investigators. *Neurology* 1993; 43: 32–36.
21 Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003; 349: 1019–1026.
22 Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in japanese patients with atrial fibrillation not receiving anticoagulation therapy—pooled analysis of the shinken database, j-rhythm registry, and fushimi af registry. *Circ J* 2015; 79: 432–438.
23 Inoue H, Atarashi H, Okumura K, et al. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. *Am J Cardiol* 2014; 113: 957–962.
24 Tomita H, Okumura K, Inoue H, et al. Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: a subanalysis of the j-rhythm registry. *Int J Cardiol* 2015; 201: 308–310.
25 Kodani E, Atarashi H, Inoue H, et al. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the j-rhythm registry. *J Am Heart Assoc* 2016; 5.
26 Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial: design and rationale. *Am Heart J* 2010; 159: 331–339.
27 Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013; 369: 2093–2104.
28 Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (esc). *Europeo* 2010; 12: 1360–1420.
29 Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: an update of the 2010 esc guidelines for the management of atrial fibrillation—developed with the special contribution of the european heart rhythm association. *Europeo* 2012; 14: 1385–1413.
30 Jung BC, Kim NH, Nam GB, et al. The korean heart rhythm society’s 2014 statement on antithrombotic therapy for patients with nonvalvular atrial fibrillation: Korean Heart Rhythm Society. *Korean Circ J* 2015; 45: 9–19.
31 National Clinical Guideline C. National institute for health and clinical excellence: Guidance. *Atrial fibrillation: the management of atrial fibrillation*. London: National Institute for Health and Care Excellence (UK) Copyright (c) National Clinical Guideline Centre, 2014.
32 De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper. *J Am Coll Cardiol* 2012; 59: 1413–1425.
33 Coppers M, Eikelboom JW, Hart RG, et al. The cha2ds2-vasc score identifies those patients with atrial fibrillation and a cha2ds2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. *Eur Heart J* 2013; 34: 170–176.
34 Friborg L, Skeieholm M, Terent A, et al. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a cha2ds2-vasc score of 1. *J Am Coll Cardiol* 2015; 65: 225–232.
Eckman MH, Singer DE, Rosand J, et al. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2011; 4: 14–21.

Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. *J Am Coll Cardiol* 2015; 65: 1385–1394.

Huang D, Anguo L, Yue WS, et al. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1. *Pacing Clin Electrophysiol* 2014; 37: 1442–1447.

Ariesen MJ, Claus SP, Rinkel GJ, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. *Stroke* 2003; 34: 2060–2065.

Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the bleeding with antithrombotic therapy (BAT) study. *Stroke* 2010; 41: 1440–1444.

Hart RG, Tonarelli SB, Pearce LA, et al. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. *Stroke* 2005; 36: 1588–1593.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994; 154: 1449–1457.

Lip GY. Thromboprophylaxis for atrial fibrillation. *Lancet* 1999; 353: 4–6.

Shantsila E, Lip GY. Preventing thrombosis to improve outcomes in heart failure patients. *Prog Cardiovasc Dis* 2016; 58: 386–392.